SynthesisBlood2018
Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma.
Open access · bronzeAbstract readMeta-Analysis
In one paragraph
Synthesis in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 3 pooled it
1.7field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Cross-cancer pleiotropic analysis identifies three novel genetic risk loci for colorectal cancer.Human molecular genetics · 2023Pooled it
- Association of Single-Nucleotide Variants in the Human Leukocyte Antigen and Other Loci With Childhood Hodgkin Lymphoma.JAMA network open · 2022Pooled it
- Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes.Human genomics · 2019Pooled it
- A genome-wide association study integrated with single-cell and bulk profiles uncovers susceptibility genes for nasopharyngeal carcinoma involved in tumorigenesis via regulation of T cells.Genome biology · 2025Article
- Integration of transcriptome-wide association study and gene-based association analysis identifies candidate genes for Hodgkin lymphoma.Journal of cancer research and clinical oncology · 2025Article
- Improve the model of disease subtype heterogeneity by leveraging external summary data.PLoS computational biology · 2023Article
- Identification and Interpretation of eQTL and eGenes for Hodgkin Lymphoma Susceptibility.Genes · 2023Article
- Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma.Journal of clinical medicine · 2022Review
- NFkB Pathway and Hodgkin Lymphoma.Biomedicines · 2022Review
- Meiotic drive in chronic lymphocytic leukemia compared with other malignant blood disorders.Scientific reports · 2022Article
- Killer Cell Immunoglobulin-Like Receptor Haplotype B Modulates Susceptibility to EBV-Associated Classic Hodgkin Lymphoma.Frontiers in immunology · 2022Article
- Interaction between ERAP Alleles and HLA Class I Types Support a Role of Antigen Presentation in Hodgkin Lymphoma Development.Cancers · 2021Article
- Peripheral T cell lymphomas: from the bench to the clinic.Nature reviews. Cancer · 2020Review
- Identifying Transcriptomic Signatures and Rules for SARS-CoV-2 Infection.Frontiers in cell and developmental biology · 2020Article
- Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk.Blood · 2019Article
- Precision Medicine in Lymphoma by Innovative Instrumental Platforms.Frontiers in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 12 institutions in 7 countries.
Amit SudDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-6133-0164
Hauke ThomsenDivision of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany.ORCID 0000-0001-5951-3116
Giulia OrlandoDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.
Asta FörstiDivision of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany.
Philip J LawDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0001-9663-4611
Peter BroderickDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-8348-5829
Rosie CookeDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.
Fadi HaririDepartment of Human Genetics, McGill University and Genome Quebec Innovation Centre, McGill University, Montreal, QC, Canada.
Tomi PastinenDepartment of Human Genetics, McGill University and Genome Quebec Innovation Centre, McGill University, Montreal, QC, Canada.ORCID 0000-0003-4016-5021
Douglas F EastonCentre for Cancer Genetic Epidemiology, Department of Oncology, and.
Paul D P PharoahCentre for Cancer Genetic Epidemiology, Department of Oncology, and.ORCID 0000-0001-8494-732X
Alison M DunningCentre for Cancer Genetic Epidemiology, Department of Oncology, and.ORCID 0000-0001-6651-7166
Julian PetoDepartment of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Federico CanzianGenomic Epidemiology Group, German Cancer Research Center, Heidelberg, Germany.ORCID 0000-0002-4261-4583
Rosalind EelesDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-3698-6241
ZSofia Kote-JaraiDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-6329-5155
Kenneth MuirInstitute of Population Health, University of Manchester, Manchester, United Kingdom.
Nora PashayanCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
Daniele CampaDepartment of Biology, University of Pisa, Pisa, Italy.ORCID 0000-0003-3220-9944
PRACTICAL Consortium
Per HoffmannHuman Genomic Research Group, Department of Biomedicine, University of Basel, Basel, Switzerland.ORCID 0000-0002-6573-983X
Markus M NöthenInstitute of Human Genetics and.ORCID 0000-0002-8770-2464
Karl-Heinz JöckelUniversity of Duisburg-Essen, Essen, Germany.
Elke Pogge von StrandmannExperimental Tumor Research, Center for Tumor Biology and Immunology, Clinic for Hematology, Oncology and Immunology, Philipps University, Marburg, Germany.
Anthony J SwerdlowDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0001-5550-4159
Andreas EngertDepartment of Internal Medicine, University Hospital of Cologne, Cologne, Germany.ORCID 0000-0003-2866-942X
Nick OrrDivision of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom; and.ORCID 0000-0001-6611-6979
Kari HemminkiDivision of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany.ORCID 0000-0002-2769-3316
Richard S HoulstonDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-5268-0242
Institute of Cancer Research · GBGerman Cancer Research Center · DEUniversity of Cambridge · GBMcGill Genome Centre · CAUniversity of Bonn · DELondon School of Hygiene & Tropical Medicine · GBPhilipps University of Marburg · DERoyal Marsden NHS Foundation Trust · GBUniversity Hospital Cologne · DEUniversity of Duisburg-Essen · DEUniversity of Manchester · GBUniversity of Pisa · IT
Funding
Epidemiological and Clinical Translational Studies Post Genome-Wide AssociationU19CA148537 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI EASTON, DOUGLAS FREDERICK, EELES, ROSALIND · 2010 to 2014
$10.4MImputation-based approach to identify low frequency variants in prostate cancerU01CA188392 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SCHUMACHER, FREDRICK RAY · 2014 to 2016
$1.9MCancer Research UK 10118Cancer Research UK 10119Cancer Research UK 14136Cancer Research UK 16561Cancer Research UK 16563Cancer Research UK 17528Cancer Research UK C1287/A16563Cancer Research UK C1298/A8362Cancer Research UK C16913/A6135Cancer Research UK C490/A10124Cancer Research UK C5047/A10692Cancer Research UK C5047/A3354Cancer Research UK C5047/A7357Cancer Research UK C570/A16491Cancer Research UK C8221/A19170Medical Research Council 1000143Medical Research Council G0000934Medical Research Council G0401527Medical Research Council G1000143Medical Research Council MR/M012190/1Medical Research Council MR/N003284/1NCI NIH HHS U01 CA188392NCI NIH HHS U19 CA148537NHLBI NIH HHS HHSN268201200008CNHLBI NIH HHS HHSN268201200008IWellcome TrustWellcome Trust 068545/Z/02Wellcome Trust 090532/Z/09/Z
Abstract
To further our understanding of inherited susceptibility to Hodgkin lymphoma (HL), we performed a meta-analysis of 7 genome-wide association studies totaling 5325 HL cases and 22 423 control patients. We identify 5 new HL risk loci at 6p21.31 (rs649775;
Indexed as
Polymorphism, Single NucleotideCell Line, TumorGene Expression Regulation, NeoplasticGenetic LociGenetic Predisposition to DiseaseGenome-Wide Association StudyGerminal CenterHistone CodeHodgkin DiseaseHumansImmunityNF-kappa BPromoter Regions, GeneticT-LymphocytesNF-kappa B
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.